Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 8,367 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: serum sample Clear all
Active, not recruiting Phase 2 Interventional Results available

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

NCT03341936
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Lirilumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

NCT00275509
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 16, 2026, 5:08 AM EDT
Terminated Phase 1 Interventional

Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

NCT04203875
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
Orencia® (Abatacept)
Drug
Lead sponsor
Stuart Knechtle, M.D.
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

NCT02523469
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
ALT-803, Nivolumab
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Weston, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 16, 2026, 5:08 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System

NCT01543295
View directory record Official record
Conditions
Syphilis
Interventions
Not listed
Lead sponsor
Chembio Diagnostic Systems, Inc.
Industry
Eligibility
13 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 3 Interventional

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

NCT00049751
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
54
States / cities
Mobile, Alabama • Apple Valley, California • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01412879
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bendamustine hydrochloride, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, methotrexate, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
204
States / cities
Duarte, California • Aurora, Colorado • Boulder, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 16, 2026, 5:08 AM EDT
Active, not recruiting Phase 2 Interventional

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

NCT05718869
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Tafasitamab, Zanubrutinib
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Duarte, California • Irvine, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

NCT00410605
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bevacizumab, lenalidomide, dexamethasone
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

NCT01695239
View directory record Official record
Conditions
Psoriasis, Arthritic
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 16, 2026, 5:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

NCT04319224
View directory record Official record
Conditions
Cancer
Interventions
Vopratelimab, Ipilimumab, Nivolumab
Drug
Lead sponsor
Jounce Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

NCT02660580
View directory record Official record
Conditions
Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
MSB11022, Humira®
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
San Luis Obispo, California • Coral Gables, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Not applicable Interventional

Flax Lignans and Heart Health

NCT01314586
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
secoisolariciresinol diglucoside-containing extract of flaxseed
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
40 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Mixed Exercise and Metabolic Stress in Relationship to Age in Healthy Men

NCT01800370
View directory record Official record
Conditions
Healthy
Interventions
Hyperglycemia, Saline, Exercise, Blood Draws, Fasting procedure
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

NCT00373256
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Sunitinib, paclitaxel, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
241
States / cities
Bessemer, Alabama • Birmingham, Alabama • Daphne, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea

NCT01447251
View directory record Official record
Conditions
Obstructive Sleep Apnea, Diabetes Mellitus
Interventions
PreDx Diabetes Risk Score
Behavioral
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 16, 2026, 5:08 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging, by Comparing to a Placebo

NCT06804772
View directory record Official record
Conditions
Skin Aging
Interventions
Investigational Facial Serum #3, Investigational Facial Serum #1, Investigational Facial Serum #2
Other
Lead sponsor
Victoria Collotta
Industry
Eligibility
35 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 16, 2026, 5:08 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

NCT01937117
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron emission tomography (PET), Trastuzumab, Pertuzumab
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 16, 2026, 5:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation

NCT01820117
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, Ophthalmology Examination
Other · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 16, 2026, 5:08 AM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

NCT02420717
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin, Laboratory Biomarker Analysis, Leucovorin, Mercaptopurine, Methotrexate, Prednisone, Rituximab, Ruxolitinib Phosphate, Vincristine
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 16, 2026, 5:08 AM EDT
Terminated No phase listed Observational

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

NCT01582568
View directory record Official record
Conditions
Crohns Disease
Interventions
Certolizumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 16, 2026, 5:08 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

NCT03636373
View directory record Official record
Conditions
Gout Attack
Interventions
Etanercept, Triamcinolone Acetonide
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 16, 2026, 5:08 AM EDT
Completed Phase 3 Interventional Results available

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

NCT00301366
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
alpha-1 proteinase inhibitor (human)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 16, 2026, 5:08 AM EDT